



Karolinska  
Institutet



Karolinska Comprehensive Cancer Center

# Kliniska studier vid Tema Cancer – 2025 –

Från Tema Cancers studiedatabas

14 jan 2026

Sammanställt av Mats Hellström, Johanna Vernersson, ME CKC

# Sammanfattning

- **Den totala inklusionen ökade under 2025 jämfört med 2024**
- **Av samtliga öppna studier är andelen akademiska studier fortsatt hög, 68 %**
- **Av öppna läkemedelsprövningar är andelen företagssponsrade prövningar 67%**
- **69 nya studier startade under 2025**, jämfört med 57 under 2024
  - Av dessa var 48 kliniska läkemedelsprövningar vilket är en tydlig ökning från 31 nya läkemedelsprövningar 2024
- **Fas 1-verksamheten fortsätter att växa** och har ökat både:
  - Antalet inkluderade patienter till 74 (från 46 under 2024)
  - Antalet öppna studier till 27 (jämfört med 20 under 2024)

Statistiken kommer från Tema Cancers studiedatabas. Alla kliniska studier som pågår inom Tema Cancer finns registrerade i databasen.

Statistiken presenteras per ME (Medicinsk enhet). För mer detaljerad statistik, kontakta [mats.hellstrom@regionstockholm.se](mailto:mats.hellstrom@regionstockholm.se)

# Tema Cancer – Studieverksamheten 2025

## Hela 2025

**3095** inkluderade patienter (2024: 2854 pat)

**69** nya studier startade (2024: 57 studier )

## 31 december 2025

**419** aktiva studier (2024: 411), varav:

- **217** studier (2024: 179) öppna för inklusion

- **202** stängda studier (2024: 232) med behandling och/eller uppföljning

# Tema Cancer – Studier öppna för inklusion 31 dec 2025


Medicinsk enhet	Antal öppna för inkl	Varav akademiska studier	Typ av pågående studie															Startade studier 2025	Pågående *
			Läke-medel	Fas 1	Fas 2	Fas 3	Övr	ATMP/Cell-/Genterapi	Fas 1	Fas 2	Fas 3	Kirurgi	Prov-tagn	Om-vårdn	Upp-följng	Strål	Med-tekn/Övr		
Bröst, Endokrin & Sarkom	<b>22</b>	73 % (16)	11	1	3	7	0	0	-	-	-	3	2	2	2	1	1	<b>12</b>	<b>48</b>
Bäckencancer	<b>39</b>	77 % (30)	15	2	4	8	1	0	-	-	-	9	9	0	3	2	1	<b>9</b>	<b>74</b>
CAST	<b>8</b>	63 % (5)	2	0	1	1	0	2	1	0	1	0	1	2	1	0	0	<b>2</b>	<b>24</b>
CKC (Fas 1)	<b>22</b>	14 % (3)	19	15	3	1	0	2	2	0	0	0	1	0	0	0	0	<b>11</b>	<b>29</b>
Hematologi	<b>24</b>	54 % (13)	16	2	4	9	1	0	-	-	-	0	6	0	1	1	0	<b>7</b>	<b>76</b>
Huvud-Hals-, Lung, Hudcancer	<b>38</b>	74 % (28)	17	2	3	12	0	1	1	0	0	2	8	2	1	7	0	<b>8</b>	<b>63</b>
Strål	<b>8</b>	100 % (8)	-	-	-	-	-	-	-	-	-	-	1	0	0	7	0	<b>3</b>	<b>11</b>
Övre buk	<b>56</b>	79% (44)	12	1	3	8	0	0	-	-	-	7	26	8	3	0	0	<b>19</b>	<b>94</b>
<b>Tema Cancer</b>	<b>217</b>	<b>68 % (147 st)</b>	<b>92</b>	<b>23</b>	<b>21</b>	<b>46</b>	<b>2</b>	<b>5</b>	<b>4</b>	<b>0</b>	<b>1</b>	<b>21</b>	<b>54</b>	<b>14</b>	<b>11</b>	<b>18</b>	<b>2</b>	<b>71</b>	<b>419</b>
31.12.2024	<b>179</b>	70 %	<b>72</b>	17	16	37	2	<b>4</b>	3	0	1	<b>13</b>	<b>48</b>	<b>15</b>	<b>10</b>	<b>16</b>	0	2024: 57	<b>411</b>

# Tema Cancer – Inklusionen 2025

Medicinsk enhet	Inkl 2025	...varav...														
		Läke-medel	Fas 1	Fas 2	Fas 3	Övr	Cell-/gen-terapi	Fas 1	Fas 2	Fas 3	Kirurgi	Prov-tagn	Om-vård	Upp-följn.	Strål	
Bröst, Endokrin & Sarkom	<b>210</b>	45	2	23	20	0	0					45	33	31	53	3
Bäckencancer	<b>893</b>	83	5	37	34	7	0					552	216	5	23	14
CAST	<b>16</b>	2	0	0	2	0	1	0	0	1		0	2	11	0	0
CKC (Fas 1)	<b>70</b>	50	46	4	0	0	4	4	0	0		0	16	0	0	0
Hematologi	<b>288</b>	73	9	34	30	0	0					0	213	0	3	2
Huvud-, Hals-, Lung-, Hudcancer	<b>580</b>	53	1	1	51	0	0					13	378	74	37	25
Strål	<b>130</b>	-					-					-	57	0	0	73
Övre buk	<b>905</b>	28	7	3	18	0	0					99	668	98	12	0
<b>Tema Cancer</b>	<b>3095</b>	<b>334</b>	<b>70</b>	<b>102</b>	<b>155</b>	<b>7</b>	<b>5</b>	<b>4</b>	<b>0</b>	<b>1</b>	<b>709</b>	<b>1583</b>	<b>219</b>	<b>128</b>	<b>117</b>	
2024	<b>2838</b>	337	43	107	143	44	4	3	1	0	269	1667	331	137	93	


Fas 1 = Fas 0, 1, 1-2; Fas 2 = Fas 2, 2-3; Fas 3 = Fas 3, 4; Övr = Pilot, ej angivet

# Tema Cancer – Inklusionen fördelad på typer av studier 2019–2025




# Tema Cancer – Inklusionen i läkemedelsstudier 2019–2025

– fördelat på *fas*




# Tema Cancer – Inklusionen i läkemedelsstudier 2023–2025

## – fördelat på *diagnosgrupper*




# Tema Cancer – Inklusionen i läkemedelsstudier 2023–2025

– fördelat på *sponsortyp*




# Tema Cancer – Inklusionen i läkemedelsstudier 2023–2025

## – fördelat på *sponsortyp* och *diagnosgrupper*




# Tema Cancer – Startade studier 2025




69 startade studier,  
 fördelat på *studietyp*  
 \* Övriga = Medtekn, Uppföljning

...varav 48 Läkemedelsstudier (inkl ATMP),  
 fördelat på *sponsortyp*

# Tema Cancer – Läkemedelsstudier startade 2025




48 startade läkemedelsstudier (inkl ATMP),  
 fördelat på *sponsortyp*




48 startade läkemedelsstudier (inkl ATMP),  
 fördelat på *sponsortyp och fas*

## Tema Cancer – Fas 1- och First in Humanstudier 2019–2025

### Studier öppna för inklusion 31 dec




### Pågående studier 31 dec




# Tema Cancer – Fas 1- och First in Humanstudier 2019–2025

– Antal inkluderade patienter per år

– First in Human / Icke First in Human



– Solida tumörer / Hematologiska sjukdomar




# ME Bröst, endokrina tumörer, sarkom


## Status 31 december 2025

Pågående studier	48
Öppna för inklusion	22
Akademiska studier	73 %
Nya studier 2025	12

Inklusion per diagnos



Inklusion per studietyp




# ME Bäckén


## Status 31 december 2025

Pågående studier	74
Öppna för inklusion	39
Akademiska studier	77 %
Nya studier 2025	9

### Inklusion per diagnos



### Inklusion per studietyp




# ME Hematologi


Status 31 december 2025

Pågående studier	75
Öppna för inklusion	24
Akademiska studier	54 %
Nya studier 2025	7

Inklusion per diagnos



Inklusion per studietyp




# ME Huvud-Hals, Lunga, Hud


Status 31 december 2025

Pågående studier	63
Öppna för inklusion	38
Akademiska studier	74 %
Nya studier 2025	8

Inklusion per diagnos



Inklusion per studietyp




# ME Övre buk


Status 31 december 2025

Pågående studier	94
Öppna för inklusion	54
Akademiska studier	78 %
Nya studier 2025	17

Inklusion per diagnos



Inklusion per studietyp




# Strålbehandling

Status 31 december 2025

Pågående studier	11
Öppna för inklusion	8
Akademiska studier	100 %
Nya studier 2025	3

Total inklusion/år




# ME CAST

## Status 31 december 2025

Pågående studier	24
Öppna för inklusion	8
Akademiska studier	63 %
Nya studier 2025	2


## Inklusion per studietyp



# ME CKC Fas 1 (cancerstudier)

## Status 31 december 2025


Pågående studier	29
Öppna för inklusion	22
Akademiska studier	14 %
Nya studier 2025	11



# ME CKC Fas 1 Huddinge (icke-cancerstudier)

## Status 31 december 2025

Pågående studier	13
Öppna för inklusion	6
Akademiska studier	15 %
Nya studier 2025	1



## Inklusion i provtagningsstudier

År	Inkl
2020	221
2021	124
2022	174
2023	160
2024	165
2025	33


# ME CKC CTO: Antal pågående akademiska studier

## 31 december 2025

CTO studiekoordinatorer, monitorerar och upprättar studiedatabas mm i dessa studier

Tema Cancer ME	Alla studier		Studier där Karolinska är sponsor			
	Alla	Varav läke-medel	Alla	Varav läke-medel	Multi-center	Multi-nationell
BES	15	10	8	8	6	3
Bäcken	20	10	10	3	6	2
CAST	2	2	1	1	1	1
CKC	4	2	0	-	-	-
Hematologi	14	12	6	5	4	2
HHLH	16	12	10	5	5	1
Strål	3	-	3	-	2	0
Övre buk	5	4	4	4	3	2
<b>TEMA CANCER</b>	<b>79</b>	<b>52</b>	<b>42</b>	<b>26</b>	<b>27</b>	<b>11</b>
Sponsor annat tema	14	11	9	8	5	4
Annan sponsor	1	0	-	-	-	-
<b>Totalt</b>	<b>94</b>	<b>63</b>	<b>51</b>	<b>34</b>	<b>32</b>	<b>15</b>

# ME CKC CTO: Fördelning av studier per ME



# Studier öppna för inklusion 2025

Här redovisas alla kliniska studier inom Tema Cancer som var öppna för inklusion under 2025. Studierna kan ha öppnat eller stängt under året, eller varit öppna hela året.

# ME BES – Bröstcentrum (1)

Studie		Prövare	Start	Inkl 2025	Total Inkl
TailorDose II	TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer	Oscar Wiklander	15.06.2017	13	161
CAPItello-292	A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer	Theodoros Foukakis	07.12.2021	2	4
Neo-ACT	Physical exercise during neoadjuvant chemotherapy for breast cancer as a means to increase pathological complete response rates: the randomized Neo-ACT trial	Kristina Weibring	18.11.2022	8	53
ARIADNE	A Randomized Trial on Biology-Driven De-escalation of Neoadjuvant Treatment for HER2-positive Breast Cancer	Alexios Matikas	18.07.2023	19	52
CARDIOCARE	CARDIOCARE: AN INTERDISCIPLINARY APPROACH FOR THE MANAGEMENT OF THE ELDERLY MULTIMORBID PATIENT WITH BREAST CANCER THERAPY INDUCED CARDIAC TOXICITY	Andri Papakonstantinou	19.12.2023	11	36
Taormina	Treatment of Oligometastatic breast cancer – a randomised phase 3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1st line treatment	Kristina Weibring	17.01.2024	3	5
LION Trial and LION-COM	Demonstrating the (cost-)effectiveness of a personalized live-remote exercise intervention for cancer survivors using a super umbrella randomized clinical trial: The LION RCT	Yvonne Wengström	10.10.2024	23	24
MK2870-010 TroFuse-010	An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer	Alexios Matikas	13.11.2024	2	3

## ME BES – Bröstcentrum (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
C4391025 (FourLight-2)	An Interventional, Open-Label, Randomized, Multicenter Phase 2 Study of PF- 07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older with Hormone Receptor-Positive, HER2-Negative Breast Cancer in the Neoadjuvant Setting	Theo Foukakis	14.02.2025	0	0
TREAT ctDNA	Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)	Theodoros Foukakis	12.03.2025	0	0
MagStage	Magnetkameraundersökning för att detektera metastaser i portvaktkörteln vid bröstcancerkirurgi där magnetiskt spårämne används.	Helena Sackey	01.04.2025	10	10
HER2-Ex PET	A multicentre, prospective, open-label study to with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2-antibody drug conjugates in patients with metastatic breast cancer.	Oscar Wiklander	04.06.2025	3	5
FOURLIGHT-3	An interventional, open-label, randomised, multicentre phase 3 study of PF-07220060 plus letrozole compared to cdk4/6 inhibitor plus letrozole in participants over 18 years of age with advanced/metastatic breast cancer who have not received any prior systemic anticancer treatment for advanced/metastatic disease	Oscar Wiklander	05.06.2025	0	0

## ME BES – Bröstcentrum (3)

Studie		Prövare	Start	Inkl 2025	Total inkl
SentiNot 2.0	Use of superparamagnetic iron oxide (SPIO) tracer to avoid unnecessary sentinel node biopsies (SNB)	Helena Sackey	25.09.2025	1	1
Destiny Breast Respond HER2-low Europe	A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy	Andri Papakonstantinou	30.10.2025	3	4
iTRANSLATE-BREAST	Intergrate real-life platform for biomarker discovery and outcome-based translational research for breast cancer patients	Andri Papakonstantinou	10.11.2025	3	3
MK2870-032	Randomized Phase 3 Open-label Active Controlled Study of Sacituzumab Tirumotecan (sac-TMT / MK-2870) in Early Triple Negative Breast Cancer (eTNBC)	Theodoros Foukakis	25.11.2025	0	0
MK2870-012 TroFuse-012	A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surger	Theo Foukakis	28.11.2025	0	0
SentiNeo 2.0	Axillary lymph node localisation before neoadjuvant chemotherapy using MagTrace, (superparamagnetic iron oxide nanoparticles, SPIO) and Magseed, in clinically node negative and node positive patients: SENTINEO 2.0	Helena Sackey	05.12.2025	0	0

# ME BES – Endokrina tumörer och sarkom

Studie		Prövare	Start	Inkl 2025	Total inkl
Parafys	Primär hyperparathyroidism hos äldre – fysisk träning för att förbättra muskelfunktion, balans och kognitiv förmåga	Inga-Lena Nilsson	01.09.2020	0	18
Kogni-Thyr-studien	Prospective longitudinal evaluation of objective cognitive function and quality of life in patients undergoing surgery for malignant and benign thyroid nodules Cognition and QoL in patients undergoing thyroid surgery	Karin Lind	03.01.2022	44	188
ADIUVO-2	Adjuvant mitotane vs. mitotane with cisplatin/etoposide after primary surgical resection of localised adrenocortical carcinoma with high risk of recurrence (ADIUVO-2 Trial): A pragmatic, randomised, low-intervention phase III, clinical trial with an observational arm.	David Goldstein	16.10.2024	2	2
START-NET	Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors An open-label, multi-center, randomized phase III controlled trial comparing safety and efficacy of trial comparing safety and efficacy of personalized vs non-personalized personalized vs non-personalized radionuclide therapy with <sup>177</sup> Lu-DOTATOC	David Goldstein	30.11.2024	3	3
PERELI	A phase 2, open label study of PEmigatinib and RETifanlimab in advanced dedifferentiated LIposarcoma	Andri Papakonstantinou	03.09.2025	1	1

# ME BES – Ärftlig cancer

Studie		Prövare	Start	Inkl 2025	Total inkl
PREP	PREvention and Prediction of breast-and ovarian cancer - PREP	Angelique Flöter Rådestad	01.08.2022	30	100
TUBA-WISP II	Tubectomy with delayed oophorectomy as alternative for risk reducing salpingo-oophorectomy in BRCA-women to assess the safety of prevention	Angelique Flöter Rådestad	01.01.2024	29	44

# ME Bäckén – Blåsa

Studie		Prövare	Start	Inkl 2025	Total inkl
BioBladder	Biomarker profiling to predict response and survival in patients receiving systemic therapy for advanced urothelial cancer	Anders Ullén	10.03.2022	81	255
RWD Avelumab	A Swedish nationwide real-world data study of maintenance avelumab in patients with advanced urothelial cancer without progression following first-line platinum-based chemotherapy	Faith Jawdat	15.08.2022	0	42
V940-005-00-Blåsa	A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-Risk Muscle-Invasive Urothelial Carcinoma Post-Radical Resection	Anders Ullén	01.06.2024	1	1
SGNDV-001/KN-D74	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2	Anders Ullén	10.12.2024	1	1

# ME Bäckén – Gynekologi (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
RACC	The RACC trial -Robot Assisted Approach to Cervical Cancer	Henrik Falconer	27.05.2019	14	165
GeMore-studien	Genetisk och molekylär kartläggning samt riktad behandling inom gynekologisk cancer	Josefin Fernebro	02.01.2021	28	259
SCAN-Mi-studien-cervix	Mikrobiomets associerade biomarkörers betydelse för utveckling och prognos av livmoderhals- och huvudhals-cancer.	Henrik Falconer	01.05.2021	2	41
ISGA-studien (pre-GAT01)	studier av immunsystemet hos patienter med gyncancer	Emelie Wallin	21.10.2021	17	124
TITANIUM	GestaTlonal TrophoblAstic Neoplasla assessMent	Ulrika Joneborg	01.01.2022	12	35
ct-DNA-studien på cervixcancer	Analys av cell-fritt tumör-DNA i blod.	Kristina Hellman	01.01.2022	15	54
DOVACC	A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer	Josefin Fernebro	25.01.2023	1	9
KANDOVA	KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID)of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.	Hanna Dahlstrand	26.04.2023	0	5
FOLERO	Frailty, quality Of Life and Early Reversal of temporary defunctioning Stoma in Ovarian Cancer	Sahar Salehi	29.02.2024	60	111

## ME Bäckén – Gynekologi (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
MK2870-005/ENGOT-en23	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy	Magnus Frödin-Bolling	23.04.2024	3	4
MK2870-020 TroFuse-020	A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line or Third-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (MK-2870-020/GOG-3101/ENGOT-Cx20)	Kristina Hellman	30.10.2024	4	5
PARP-PET	[11C]AZ14193391 - PET as a selection tool for treatment with PARP inhibitors in patients with metastatic solid tumors	Josefin Fernebro	30.01.2025	7	17
GROINSS VIII	GROningen INternational Study on Sentinel node in Vulvar Cancer III, a prospective phase II treatment trial	Christina Hellman	02.05.2025	1	1
DARSH-studien	Day care in Robotic Surgery Hysterectomy. Jämförande studie mellan dagvård och inneliggande vård vid robot-assisterad hysterektomi	Vilhelm Mörlin	01.08.2025	20	22

# ME Bäckén – Kolorektal (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
CRUISE	Restorative treatment with ileorectal anastomosis or ileal pouch anal anastomosis in patients with ulcerative colitis	Caroline Nordenvall	01.03.2017	5	64
CIM-IBD	Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease	Caroline Nordenvall	13.06.2019	18	174
CIM-HIPEC	The native immune system and the development of carcinomatosis among patients with colorectal cancer	Caroline Nordenvall	10.01.2020	41	213
CITCCA pilot	Circulating Tumour DNA in Colorectal CAncer, pilotstudie	Anna Martling	22.10.2020	10	177
PRORECT	Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT): A Prospective Randomized Swedish Phase II Trial	Alexander Valdman	08.03.2021	12	75
PelvEx II	Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer	Henrik Iversen	17.08.2022	3	6
EFFIPEC	EFFIPEC – Efficacy of Hyperthermic Intraperitoneal Chemotherapy Single-arm Phase I study, followed by an open-label, randomized, controlled registry-based phase III trial	Gabriella Palmer	30.10.2022	5	17
SELSA	Selective defunctioning stoma approach in low anterior resection for rectal cancer(SELSA): a prospective study and a nested randomised clinical trial	Naseer Baloch	31.10.2024	9	11
TRIOCOL	TRIOCOL - the study of third-line advanced drug treatment vs colectomy in patients with ulcerative coliti	Caroline Nordenvall	03.11.2024	11	13

## ME Bäckén – Kolorektal (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
HILOS	HIPEC and LOng of Stay - Patienters upplevelse och erfarenheter av högspecialiserad buk- och bäckencancerkirurgi	Tina Gustavell	22.11.2024	5	17
Komplikationer efter rektalcancer/ carcinoskirurgi	Förekomst av komplikationer efter rektalcancer- och carcinoskirurgi samt påverkan på tarmfunktion och livskvalitet	Mirna Abraham Nordling	12.02.2025	381	384
SCAR-studien	Operation eller behandling med koloskop efter borttagande av tidig tarmcancer (SCAR-studien)	Richard Marsk	01.11.2025	0	0

# ME Bäckén – Njure, testikel

Studie		Prövare	Start	Inkl 2025	Total inkl
MIR-Studien	MikroRNA som markörer för monitorering av sjukdomsaktivitet, utvärdering av effekt av cytostatikabehandling, samt verktyg för tidig upptäckt av recidiv av metastatisk testikelcancer. Implentering av MIR-Studien	Anders Kjellman	23.04.2019	0	291
TINCA II - njurcancer	Det immunologiska landskapet i njurcancer	Magnus Lindskog	01.09.2021	4	44

# ME Bäckén – Prostata (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
SPCG-15	Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial	Mats Olsson	01.10.2014	4	67
PSMA recidiv-studien	En randomiserad jämförelse mellan konventionell "Salvage" strålbehandling och individualiserad PSMA-pet styrd behandling hos patienter med biokemiskt återfall (PSA) efter prostatacancer operation	Stefan Karlsson	30.10.2018	21	218
ProBio	ProBio: An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer mCRPC)	Anders Ullén	27.05.2019	14	52
MK3475-365	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Enrique Castellanos	01.04.2022	0	4
PRIS	Prostate Cancer IRE Study (PRIS) – A randomized controlled trial comparing focal to radical treatment in localized prostate cancer	Anna Lantz	07.09.2022	47	118
METRO	Metastasis directed Stereotactic Body Radiotherapy (SBRT) for Oligo metastatic Hormone sensitive Prostate Cancer	Mattias Hedman	19.10.2023	2	12
CAAA617A12402	Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer	Enrique Castellanos	30.01.2024	0	0
OMAHA-003	A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated with Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Enrique Castellanos	10.05.2024	6	8

## ME Bäckén – Prostata (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
OMAHA-004	A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)	Anna Kristiansen	01.06.2024	2	3
IPA	Incontinence Post robot assisted radical prostatectomy, Anatomical and functional causes	Stefan Carlsson	14.11.2024	12	14
AMG509-Xalute	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Chemotherapy.	Enrique Castellanos	25.05.2025	2	2
RechARge-CA0711000	A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer(mCRPC)	Enrique Castellanos	30.05.2025	4	4
MK2400-001-IDEate-Prostate01	A phase 3, open-label study of Ifinatamab Deruxtecan versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC)	Anna Kristiansen	04.06.2025	3	3
PARIS-BIO	Prostate Androgen Response Investigation using a Stratification BIOMarker	Johan Björklund	03.11.2025	5	5

# ME CAST (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
Predicting fatigue after allo HSCT	Predicting chronic fatigue and cognitive dysfunction after allogeneic hematopoietic stem cell transplant.	Katarina Le Blanc	31.01.2019	11	84
LTFU - CAR T-Cell	Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CAR T-Cell Therapy)	Stephan Mielke	15.04.2020	0	2
Transcend FL	A phase 2,open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL)	Stephan Mielke	01.02.2021	0	7
PerCent-aCent	Personcentrerad vård inom allo-HSCT	Jeanette Winterling	12.02.2021	0	11
Alexion 1210 TMA-313	A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT	Ksenia Boriskina	14.09.2022	0	3
NMDSG14-B-2	A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndrome - MDS	Andreas Björklund	16.12.2022	0	9
Claudin-6 BNT211-01	Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors	Stephan Mielke	28.05.2023	0	4

## ME CAST (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
Fatigue PET studie	Fatigue och kognitiv dysfunktion till följd av synaptopati eller Graft versus host (GVH) sjukdom i hjärnan	Katarina Le Blanc	17.04.2024	2	9
ROCKnrol-1	A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) [Protocol number: EFC17757]	Johan Törlén	01.06.2024	1	1
CA0881007-Myelom	A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5Ddirected CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomiderefractory Multiple Myeloma	Johan Törlén	20.05.2025	1	1

# ME CKC (1)

Studie		Prövare	Start	Inkl 2025	Total Inkl
Keynote-587	A multicenter, open label, phase III extension trial to study the long-term safety and efficacy in participants with advanced tumors who are currently on treatment or in follow-up in a pembrolizumab trial.	Jeffrey Yachnin	20.11.2018	0	5
PSFF STUDIE- Blodburna vävnadsprov	Screening-program med blodburna vävnadsprov för patienter med avancerad cancer - PSFF studie	Jeffrey Yachnin	12.06.2019	16	348
BoB	Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors	Luigi de Petris	18.06.2019	1	13
MonKey (BI-1206-03) bi-18	Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL1 Antibodies	Jeffrey Yachnin	15.11.2020	2	20
BIKUPAN (19-BI-1808-01)	Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies	Jeffrey Yachnin	27.01.2022	7	18
ONCORELLA-1 (ONC001-CL-001)	A phase I/II, open label, single arm study on safety, tolerability and anti-tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma	Jeffrey Yachnin	08.02.2022	1	5
CERTIS1	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)	Theodoros Foukakis	12.01.2023	4	10

# ME CKC (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
NeoGap (NEOGAP-CRC-01)	A First-In-Human, Phase I/IIa Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer	Maximilian Kordes	16.03.2023	4	5
FORE (F8394-201)	A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations	Jeffrey Yachnin	29.06.2023	2	5
BRETON (BGB-16673-101)	A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies	Kristina Sonnevi	27.09.2023	2	3
Teneriffa (22 BI-1910-01 TNFR2)	Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors	Jeffrey Yachnin	26.01.2024	2	9
MICHRO (CHRO761A12101)	An open-label, multi-center phase I/Ib dose finding and expansion study of HRO761 as single agent and in combinations in patients with Microsatellite Instability-High or Mismatch Repair Deficient advanced solid tumors	Jeffrey Yachnin	29.05.2024	5	5
CEACAM5 (C5831001 SGNCEA5C-001)	A Phase 1 Study of SGN-CEACAM5C in Advanced Solid Tumors	Luigi De Petris	05.09.2024	7	9
BEHOLD-1 (SPARTACUS B7- H4 222730)	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors	Lisa Liu Burström	19.11.2024	6	6

# ME CKC (3)

Studie		Prövare	Start	Inkl 2025	Total inkl
AKIR-001	A phase 1 prospective, open-label, first-in-human basket study to evaluate the safety, tolerability and biodistribution of [177Lu]Lu-AKIR001 and its anti-tumour effect in adult patients with CD44v6 expressing solid tumours.	Luigi De Petris	31.01.2025	6	6
ABY-271-101	A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer	Oscar Wiklander	22.05.2025	0	0
BEHOLD-2 (223559)	A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors	Lisa Liu Burström	30.05.2025	0	0
VIDAR-1	Phase 1/2 Master Protocol for Open-Label, Multi-Centre, Single-Arm Sub-Studies, First in Human Clinical Studies of TCR-T Therapy (Autologous TCR Modified T-Cell Therapy) Targeting Mutated Kirsten Rat Sarcoma (mutKRAS) Administered in Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Adult Patients with Specific mutKRAS and Human Leukocyte Antigen (HLA) Genotypes	Max Kordes	11.06.2025	0	0
HELIX (C5901001)	AN OPEN-LABEL PHASE 1 STUDY TO INVESTIGATE PF-08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS	Luigi De Petris	23.06.2025	0	0
BIWAC-2 rollover (1403-0032)	A Phase II, single-arm, open-label, long-term safety rollover trial of oral brigimadlin in patients with solid tumours	Christina Linder Stragliotto	29.07.2025	1	1

# ME CKC (4)

Studie		Prövare	Start	Inkl 2025	Total inkl
ROCKY (GO43860)	A phase Ia/Ib, open label, multicenter, dose-escalation study to evaluate the safety, pharmacokinetics, and activity of RO7502175 as a single agent and in combination with checkpoint inhibitor in patients with locally advanced or metastatic solid tumors	Luigi De Petris	29.07.2025	1	1
PAnTHA (22049)	A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of <sup>225</sup> Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)	Oscar Wiklander	22.10.2025	3	3
PRIMA (22931)	A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumor	Mark Zupancic	19.11.2025	0	0
Herkules (CA236-0001)	A Phase 1/2 Study of BMS-986482 Alone or Combination Therapy in Participants with Advanced Solid Tumors	Lisa Liu Burström	21.11.2025	0	0
KANDLELIT-014 (MK1084-014)	Phase 2, Open-Label, Multicenter, Tumor-agnostic Basket Study of MK-1084 as Monotherapy and in Combination with Cetuximab in Participants with KRAS G12C Mutant, Advanced Solid Tumors (KANDLELIT-014)	Maximilian Kordes	11.12.2025	0	0

# ME Hematologi – Benmärgssvikt och leukemi (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
MAATEO	A phase 1 study in MDS, AML and ALL patients to evaluate safety, tolerability and efficacy of Karonudib	Stefan Deneberg	03.10.2019	3	19
HOVON 150	A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy	Martin Jädersten	27.01.2021	0	3
EVI-3: Combining Active and Passive DNA Hypomethylation	EVI-3: Combining Active and Passive DNA Hypomethylation A multicenter, randomized, parallel-group, placebo-controlled phase II study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in higher-risk MDS, CMML, and low-blast-count AML	Eva Hellström Lindberg	15.04.2021	3	19
Labmarkörer MPN-patienter	Labmarkörer som en del av riskbedömning för trombohemorrhagiska komplikationer hos patienter med myeloproliferativa sjukdomar	Roza Chairati	06.12.2021	15	104
LD-VenEx	LD-VenEx Clinical Study Protocol: Phase 2 study of azacitidine in combination with low dose intensity venetoclax in patients with acute myeloid leukemia with integration of explorative multi-omics and ex vivo drug screening data	Martin Jädersten	10.05.2023	1	9

## ME Hematologi – Benmargssvikt och leukemi (2)

Studie		Provare	Start	Inkl 2025	Total inkl
MEDAL	Monitoring for Early Detection of relapse in Acute myeloid Leukemia	Martin Jadersten	12.10.2023	0	5
MK3543-006-05 Shorespan-006	A Phase 3 Multi-Center, Randomized, Controlled Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) versus Best Available Therapy (BAT) in Patients with Essential Thrombocythemia who are Resistant to or Intolerant of Hydroxyurea	Anna Ravn Landtblom	01.06.2024	3	3
MK3543-007 (Shorespan-007)	A phase 3, Randomized, Double-blind, Active.Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK3543) versus Hydroxyurea in Cytoreductive Therapy Naive Essential thrombocythemia Participants	Anna Ravn Landtblom	29.11.2024	1	1
RENEW-KER-050-D301	A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia	Magnus Tobiasson	29.04.2025	1	1
Lumina 3	A phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)	Cecilia Karlstrom	15.08.2025	0	1

# ME Hematologi – Lymfom (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
Immunologiska lab-studier på patienter med KLL och andra hematol maligniteter	In vitro studier av immunologiska funktioner hos patienter med kroniska lymfoproliferativa tumörsjukdomar (Myelom, lymfom, KLL) och MGOS: Extra blodprovstaging	Anders Österborg	01.01.2018	52	101
BioLymph	Prospektiv studie av biologi, etiologi och överlevnad vid lymfom (BioLymph).	Karin Ekström Smedby	14.02.2019	140	676
PRO-Hodgkin	Clinical investigation of PBS proton treatment in Hodgkin lymphoma patients	Lotta Hansson	06.11.2019	2	25
ALLTogether-1	ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)	Joel Joelsson	01.09.2020	4	25
POLAR-BEAR	R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7	Sara Harrysson	01.02.2021	0	0
DSA-LL-studien	Better and individualised therapy for patients with relapsing lymphoma and leukaemia	Björn Wahlin	01.09.2021	5	27
BGB3111-LTE1 Roll-overstudie	En öppen, multicenter, långsiktig förlängningsstudie av zanubrutinib (BGB-3111) hos patienter med Bcellsmaligniteter.	Björn Wahlin	10.05.2022	0	12

## ME Hematologi – Lymfom (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
PreVent-ACaLL	Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping	Jeanette Lundin	15.08.2022	0	0
MERLIN	Phase II multicenter clinical trial: Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic countries	Björn Wahlin	14.12.2023	4	10
BELLWAVE-011 (MK1026-011)	A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Anders Österborg	10.10.2024	13	16
HYPERION	Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial	Björn Wahlin	08.11.2024	16	18
Golseek-1	A phase 3, multicenter, Randomized, Double-blind, Placebo-controlled study comparing the efficacy and safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP chemotherapy in participants with Previously untreated High-risk large B-Cell Lymphoma.	Kristina Sonnevi	24.01.2025	2	2
SOUNDTRACK-B	A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Björn Wahlin	06.05.2025	3	3
NLG-FL7 FLIRT	Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL	Björn Wahlin	05.06.2025	10	10

## ME Hematologi – Lymfom (3)

Studie		Prövare	Start	Inkl 2025	Total inkl
RITZ	Phase 3, interventional, multicentre, open label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)	Björn Wahlin	25.11.2025	2	2
BGB-11417-303	A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Lotta Hansson	01.12.2025	0	0

## ME Hematologi – Myelom (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
MAGNETISMM-7	A randomised, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation	Katarina Uttervall	08.09.2022	3	6
MajesTEC-7	A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy	Katarina Uttervall	22.12.2022	0	2
ODX-MM-001	A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma	Katarina Uttervall	28.03.2023	6	7

## ME Hematologi – Koagulation

Studie		Prövare	Start	Inkl 2025	Total inkl
A-EKG-HemA	Kardiovaskulära risker och mikropartiklarnas roll i en åldrade population av patienter med hemofili A under olika behandlingsregim	Roza Chaireti	05.12.2019	1	11

# ME HHLH – Hudtumörer (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
MAT02	A phase I study to evaluate safety, feasibility and immunologic response of adoptive T cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma	Maria Wolodarski	02.10.2013	0	17
TRIM	TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow up after radical surgery of stage IIb-c and III cutaneous malignant Melanoma.	Hildur Helgadottir	08.06.2017	37	319
PROMMEL	Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases	Hildur Helgadottir	08.03.2021	0	12
Studie immunologisk aktivitet hos melanomtumörer	Studier av immunologisk aktivitet hos melanomtumörer som opereras bort	Hildur Helgadottir	18.10.2021	0	7
Bio-Melanom	En provsamlingsstudie för att identifiera biomarkörer av betydelse för behandlingseffekt och toxicitet vid medicinsk behandling av patienter med malignt melanom	Fernanda Costas Svedman	15.08.2022	27	48
Tumörmarkörer vid Merkelcells-carcinom	studier för att identifiera tumörmarkörer av betydelse för uppkomst, progression och behandlingseffekt vid Merkelcellscarcinom.	Lisa Villabona	29.05.2023	9	12
Melbankstudien	Studier på primära melanom och högrisk sjukdom.	Hanna Eriksson	19.06.2023	8	14

## ME HHLH – Hudtumörer (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
PRISM-MEL-301	A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)	Hanna Eriksson	10.10.2024	1	1
SCANDIUM III	A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial	Hildur Helgadóttir	24.10.2024	2	2
GRAND-SLAM	A prospective randomized international multicenter study to compare Short versus Long Adjuvant immunotherapy after radical surgery of stage IIb-c, III and IV cutaneous malignant Melanoma	Hildur Helgadóttir	17.02.2025	13	14
SWE-NEO	Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanom	Hildur Helgadóttir	10.06.2025	7	8
EIK 1001-006	A multicenter, randomized, double-blind, active comparator-controlled, adaptive Phase II/III study to evaluate the safety and efficacy of EIK 1001 and Pembrolizumab versus Placebo and Pembrolizumab as First-Line therapy in participants with Advanced Melanoma (EIK 1001-006)	Hanna Eriksson	29.09.2025	0	0

# ME HHLH – Huvud-hals

Studie		Prövare	Start	Inkl 2025	Total inkl
Artscan IV	A nonrandomized multicenter observational study of all reirradiation in patients with head and neck cancer with special focus on patients receiving proton therapy	Michael Gubanski	24.04.2019	2	29
ARTSCAN V	Photon therapy versus proton therapy in early tonsil cancer	Michael Gubanski	06.08.2019	5	19
Öppna biopsier vid lymfomutredning	Studie av öppna biopsier av lymfkötlar i samband med lymfomutredning och icke palpabla halscystor	Rusana Bark	15.04.2021	6	15
Predict-HPV-HNC	Studier på markörer för bättre prognosbedömning, uppföljning och behandling av humant papillomvirus positiv huvudhalscancer	Mark Zupancic	25.01.2024	50	118
JADE/219885	A randomized, double-blind, placebo-controlled phase 3 study to evaluate Dostarlimab as sequential therapy after chemoradiation in participants with locally advanced unresected Head and Neck squamous cell carcinoma	Hanna Carstens	15.08.2024	0	1
PRO-GLIO	PROton versus photon therapy in IDH-mutated diffuse grade 2 and 3 GLIOMas	Mark Zupancic	15.10.2024	3	3
Nodequest-sentinal node teknik	Kan Sentinal Node teknik förbättra utfall vid cervikal lymfkörtelutrymning för metastaserad hudcancer?	Mathias von Beckerath	01.03.2025	7	8
HH-Prog-Markör-studien	Prognostiska markörer för bättre uppföljning av huvud-halscancer (som opereras)	Mathias von Beckerath	11.12.2023	0	5

# ME HHLH – Lunga (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
PreDDLung-studien	Biomarköranalyser för utveckling av diagnostik och skräddarsydd behandling vid tumörer i andningsorganen	Simon Ekman	10.05.2021	254	909
Immu-LC-studien	Det immunologiska landskapet- lungcancer, The immunological landscape in lung cancer. Studies of effector mechanisms and biomarkers in patients with NCLC undergoing treatment with checkpoint inhibitors	Luigi De Petris	25.10.2021	30	134
MO41552-ROS 1	A randomised, open label, multicentre, phase 3 study of entrectinib versus crizotinib in patients with locally-advanced or metastatic non-small cell lung cancer harbouring ROS1 gene rearrangements with and without central nervous system metastases	Karam Al Jirf	30.03.2022	0	5
PROTHYM	Phase II non-randomized study on Proton Radiotherapy Of Thymic Malignancies	Karin Lindberg	19.04.2022	0	9
LUCA-S	Web-based symptom monitoring and survival in advanced stage lung cancer	Gunnar Wagenius	01.12.2022	25	73
ASAB	ASAB - Alectinib followed by concomitant consolidation SBRT/hypofractionated radiation therapy in advanced NSCLC with ALK-rearrangement	Karin Lindberg	13.12.2022	1	2
M18-868-Teliso	Phase 3, open-label, randomized, controlled, global study in subjects with c-Met overexpressing (c- Met+), EGFR wildtype, locally advanced/metastatic non-squamous NSCLC that has progressed after standard of care therapy.	Karam Al Jirf	20.02.2023	0	2
TRIPLEX	Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy (TRT) to durvalumab immunotherapy plus chemotherapy in extensive stage small-cell lung cancer	Luigi De Petris	06.04.2023	6	26

## ME HHLH – Lunga (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
K-SAB	Sotorasib followed by SBRT to 1-3 lesions in advanced NSCLC with KRASG12C mutation	Karin Lindberg	20.06.2023	0	4
ERIS	EGFR-mutated lung cancer in randomized investigator initiated study. ERIS is a national, randomized phase III trial for advanced NSCLC harboring targetable EGFR mutations.	Simon Ekman	18.09.2023	9	33
BO42777 HORIZON01	A phase 1-3, multicenter study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status, with locally advanced, unresectable, stage III non-small cell lung cancer	Karam Al Jirf	20.12.2023	0	1
ANDROMEDA	Addition of hypofractionated high dose radiation in oligometastatic disease - An open label randomized phase III trial comparing up-front radiation in oligometastatic non-small cell lung cancer (NSCLC) and systemic treatment with systemic treatment alone	Karin Lindberg	06.02.2024	4	7
MARS	Multicentre phase III study: Addition of Radiotherapy to Standard chemotherapy for stage IV NSCLC	Signe Friesland	28.02.2024	11	19
EFS-Frailty in lung cancer	Frailty among elderly patients with advanced lung cancer	Jeanette Winterling	29.02.2024	49	84
Beamion-Lung02	A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic - non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations	Simon Ekman	27.06.2024	2	2

## ME HHLH – Lunga (3)

Studie		Prövare	Start	Inkl 2025	Total inkl
Bridge D9106C00002	A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-III B Non-small Cell Lung Cancer (NSCLC)	Karin Lindberg	15.08.2024	0	2
MK2870-009 Lunga	A Randomized Phase 3 Study of MK-2870 plus Platinum vs. MK-2870 vs. Platinum Doublets in EGFR-mutated, Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors	Simon Ekman	15.08.2024	4	7
SOLUCOM	Sotorasib in advanced KRASG12C -mutated non-small cell lung cancer patients with comorbidities (SOLUCOM)	Simon Ekman	28.10.2024	1	1
Galaxies Lung-301 (GSK4428859A)	A Randomized, Multi-Center, Double-blind, Placebo Controlled, Phase 3 Study to Investigate Safety and Efficacy of GSK4428859A in combination with Dostarlimab compared with Placebo in combination with Pembrolizumab in Participants with Previously Untreated Locally Advanced, Unresectable or Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (NSCLC)	Hannah Björn Andtback	12.02.2025	0	0
V940-009 Lung	A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)	Olof Hjorthorn	14.05.2025	2	2

## ME HHLH – Lunga (4)

Studie		Prövare	Start	Inkl 2025	Total inkl
<b>HARMONi-3 (SMT112-3003)</b>	A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3) SMT112-3003	Luigi De Petris	04.06.2025	5	5
<b>CA240-0009</b>	A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies	Luigi De Petris	15.11.2025	0	0

# ME Strålbehandling

Studie		Prövare	Start	Inkl 2025	Total inkl
PTV-marginaler vid SBRT	Marginaler vid stereotaktisk strålbehandling av tumörer i thorax, buk, bäcken och skelett	Kristin Karlsson	01.05.2021	0	205
SENS	Förutsäga individuell strålkänslighet för bröstcancerpatienter med hjälp av genetiska och inflammatoriska markörer	Mattias Hedman	13.04.2022	42	201
Andningskorrelerad PET-CT för definition av strålområdet inför strålbehandling av matstrupscancer	4D-PET-CT vid strålbehandling av esofagus cancer	Gabriella Alexandersson von Döbeln	01.01.2023	0	5
Kontaktbrachyterapi för yttlig hudcancer	Kontaktbrachyterapi för behandling av yttlig hudcancer av icke-melanom typ	Michael Gubanski	10.10.2023	8	21
RealMove (lung)	RealMove (lung): assessing tumour motion with dynamic MRI	Eva Onjukka	15.03.2024	34	45
The T-REX-Trial	Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases; an open, multicenter, randomized non-inferiority phase 3-trial.	Mattias Hedman	28.11.2024	0	0
Direktstart	Direktstart av strålbehandling på rum med CBCT baserad dosplanering	Mattias Hedman	01.02.2025	13	15
CORRECT	Contact radiotherapy in rectal cancer	Per Nilsson	13.02.2025	18	18
PARAPLY	Stråldos till blodet för att förutsäga lymfopeni hos bröst- och prostatacancer patienter - en pilotstudie	Mattias Hedman	15.09.2025	15	15

# ME Övre buk – Leversjukdom (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
PSC-Prognos/Skandpsc	Diagnostiska och prognostiska markörer vid skleroserande cholangit	Annika Bergquist	20.02.2019	8	360
PiSCATIN	Simvastatins effekt på prognos vid primär skleroserande kolangit (PSC); en randomiserad, dubbelblind, placebokontrollerad multicenterstudie	Annika Bergquist	01.10.2020	5	216
BIGMAP-studien	Biokemiska, kliniska och genetiska markörer för uppföljning och prognostisering vid levercirros	Per Stål	01.03.2021	33	224
INSPEL	Instructed home-based Physical Exercise for patients with Liver cirrhosis	Hannes Hagström	28.01.2022	2	38
Kommunikation och information vid PCS-diagnos	Patientupplevelse av kommunikation och information från sjukvården vid diagnos primär skleroserande kolangit	Tina Gustavell	01.06.2022	0	5
Helics	Hemostasis in liver cirrhosis and hepatocellur carcinoma	Per Stål	29.11.2022	46	177
ASCTRACE	En explorativ pilotstudie med syfte att kartlägga T- och B-cellers funktion i ascites och blod hos patienter med dekompenenserad levercirros med och utan spontan bakteriell peritonit (SBP)	Per Stål	26.04.2023	0	19
CHANNEL	Kartläggning av vita blodkroppars reaktion mot tumörceller hos patienter med levercellscancer – ett pilotprojekt	Per Stål	01.04.2024	16	18

## ME Övre buk – Leversjukdom (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
KALIB	Biomarkörer vid leversjukdom	Hannes Hagström	07.04.2024	41	84
TAK-999-3002	A Randomized, Double -blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F1 Fibrosis	Staffan Wahlin	10.06.2024	0	0
TAK-999-3001	A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis	Staffan Wahlin	21.08.2024	1	1
ZaniHertwo -JAZZ	An open label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advance HER2-positive biliary tract cancer.	Maria Gustafsson Liljefors	04.11.2024	0	0
NUT-022	An open-label study of patients with primary sclerosing cholangitis (PRC) treated with nurucholic acid tablets	Annika Bergqvist	30.03.2025	2	2
Pechora	A phase 1, open-label positron emission tomography trial to assess changes in liver uptake of [68Ga]Ga-FAPI-46 following oral administration of single doses of AZD2389 to patients with advanced liver fibrosis (PECHORA)	Hannes Hagström	12.05.2025	7	7
EV-HCC	Analys av extracellulära vesiklar för riskbedömning av trombos vid levercancer	Per Stål	01.09.2025	2	2
pTTL-LIVER	Personalised cell therapy, pTTL, in colorectal cancer patients with liver metastases – a feasibility study	Stefan Gilg	23.09.2025	4	4

## ME Övre buk – Leversjukdom (3)

Studie		Prövare	Start	Inkl 2025	Total inkl
STARLIGHT-222291	A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)	Hannes Hagström	17.10.2025	0	0
DETECT-HCC	A comparative study of MRI and ultrasound for detection of primary hepatocellular carcinoma, body composition and risk factors for decompensation in liver cirrhosis	Magnus Holmér	20.10.2025	3	3
RILIEF-Rilzabrutinib-EFC1735	A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib compared to placebo in adult participants with active IgG4-related diseases	Miroslav Vujasinovic	15.12.2025	0	0

# ME Övre buk – Levertumör/-metastas

Studie		Prövare	Start	Inkl 2025	Total inkl
LIVIMM	Studier av immunförsvarets celler i blod och lever hos vuxna patienter med leversjukdom.	Niklas Björkström	31.03.2016	16	235
DyNAmiC	Dynamic Profiling of Circulating Vesicle-borne Nucleic Acids in Human Liver Cancer	Stefan Gilg	01.02.2021	0	66
New COMET	En randomiserad studie mellan ablation och resektion av levermetastaser från tjock- och ändtarmscancer	Jennie Engstrand	01.12.2022	10	33
ScanPan 1	A population-based assessment of curative intended multimodal treatment in patients with oligometastatic pancreatic cancer responsive to neoadjuvant chemotherapy	Ernesto Sparrelid	01.06.2023	11	18
ROBOCOP	Robotic-assisted contra open resection for suspected or confirmed gallbladder cancer (ROBOCOP) An international, multi-centre, open-label, randomized controlled superiority trial	Christian Stureson	24.01.2024	17	32
DRAGON 2	DRAGON 2 – An international multicenter randomized controlled trial to compare combined Portal and Hepatic Vein Embolization (PVE/HVE) with PVE alone	Ernesto Sparrelid	12.06.2024	4	8

# ME Övre buk – Kolorektal

Studie		Prövare	Start	Inkl 2025	Total inkl
BNT122-01	A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection	Mia Karlberg	28.04.2023	0	0
OrigAMI-2	A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With RAS/RAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer	Mia Karlberg	27.01.2025	1	1
OrigAMI-3	A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With RAS/RAF Wild-type Recurrent Metastatic Colorectal Cancer Who Have Received or Are Intolerant to Prior Chemotherapy	Mia Karlberg	27.01.2025	1	1

# ME Övre buk – Matstrupe, magsäck (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
Biobank Esofagus/ventrikel biopsi	Studie av tumör genetiska förändringar vid cancer i matstrupe eller magsäck.	Fredrik Klevebro	05.06.2015	54	98
Funktionell radiologi-matstrupscancer	Funktionell radiologi vid ventrikeltub	Magnus Nilsson	02.12.2019	0	31
NEEDS	NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed	Magnus Nilsson	25.09.2020	4	18
Biobank eso/vent operation		Fredrik Klevebro	01.01.2022	102	168
CARDIA trial	Surgery for adenocarcinoma of the gastroesophageal junction (GREJ) type II: Transthoracic esophagectomy vs. Transhiatal extended gastrectomy	Magnus Nilsson	27.01.2022	0	4
GOPRO	Patientrapporterad livskvalitet och erfarenhet av vården efter diagnos och vid behandling av cancer i matstrupe-och magsäck.	Berit Sunde	27.11.2022	53	171
CASE-studien	Postoperativt delirium i samband med behandling av cancer i magsäck eller matstrupe	Maria Lampi	23.10.2024	21	21

## ME Övre buk – Matstrupe, magsäck (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
SARONG	Open label international multicentre randomised controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer	Maria Lampi	24.10.2024	2	4
Endeavor pilotstudie	Endoskopisk borstcytologi och singelcell klonal dynamik av tidig Barrett-neoplasi för kostnadseffektiv surveillance och prediktion av återfall: prospektiv pilot inför en randomiserad kontrollerad studie	Fredrik Klevebro	06.10.2025	2	2
JEDI	Radiologic contrast evaluation and symptoms of late delayed gastric conduit emptying after esophagectomy - the European multicenter JEDI study	Fredrik Klevebro	08.10.2025	7	7
IPa Gastric	Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy Alone in Gastric Cancer Patients with Peritoneal Metastase	Lisa Liu Burström	18.11.2025	3	3

# ME Övre buk – Pankreas (1)

Studie		Prövare	Start	Inkl 2025	Total inkl
IPMN-IMM	En studie av immunförsvarets celler i blod och mag-tarmsystemets organ hos vuxna patienter med gastrointestinala sjukdomar	Niklas Björkström	21.09.2017	13	95
FIMMUN	Immunceller och fibroblaster vid pancreassjukdom	Poya Ghorbani	03.01.2019	0	335
Tumöregenskapsstudien	Ex vivo undersökningar av mikroskopiska utseenden, proteinuttryck och molekyllärrubningar i cancrar från pancreashuvudet samt deras betydelse för överlevnad och drogresistens	Carlos Fernandez Moro	01.11.2019	20	412
FeDUP	Fecal dysbiosis and undernutrition in pancreatic cancer patients (delstudie till PanTuMiMe)	Matthias Löhr	28.02.2021	1	193
FAPI-46/FAPI-PET	PET imaging of tumors with strong desmoplastic reaction in pancreas, bile ducts and ventricle by a novel tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor	Rimma Axelsson	01.06.2021	27	223
CEL3A	Nivåer av fekalt elastas i individer med CELA3A-mutationer	Matthias Löhr	23.12.2021	0	13
Avbruten cancerkirurgi	Avbruten cancerkirurgi - ett patientcentrerat forskningsprojekt.	Tina Gustavell	01.03.2023	0	105
PRECODE	pANCreATIC Cancer OrganoiDS ReSEARCH nETWORK	Matthias Löhr	09.04.2023	0	33
PREOPANC-3	PREOPANC-3. En studie om värdet att ge cytostatikabehandling inför kurativt kirurgi vid bukspottkörtelcancer	Poya Ghorbani	23.05.2023	0	5
Anocca PDAC	A non-interventional study of patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC) in conjunction with first-line Standard of Care to determine T-cell fitness for manufacturing of future autologous cell therapies	Maximilian Kordes	01.10.2023	22	44

## ME Övre buk – Pankreas (2)

Studie		Prövare	Start	Inkl 2025	Total inkl
ProviDHe	An open-label early access phase 3b study of Ivosidenib/AG-120/S95031 in patients with a pretreated locally advanced or metastatic cholangiocarcinoma (CCA).	Maximilian Kordes	19.10.2023	1	5
GUIDE.MRD	GUIDing multi-modal therapies against Minimal Residual Disease by liquid biopsies	Marco Gerling	14.04.2024	75	117
IMCODE003-GO4479	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA	Maximilian Kordes	05.06.2024	3	4
PEI-HH (hematomakros)	Pancreatic exocrine insufficiency in patients with hemochromatosis	Miroslav Vujasinovic	20.09.2024	31	64
PANCAID	Biomarkörer i blod för tidig upptäckt av bukspottkörtelcancer	Matthias Löhr	15.01.2025	50	68
HPB multiomik Pilot	Molekylär profilering av hepatopankreatobiliär cancer	Ernesto Sparrelid	01.03.2025	55	55
PEI-Heart	Sarcopenia and pancreatic exocrine insufficiency in patients with chronic heart failure and heart transplantation	Miroslav Vujasonovic	01.06.2025	27	27
Pan-MetS	Pancreas and metabolic syndrome	Miroslav Vujasinovic	28.10.2025	23	22
BMS-CA2400030 – PMRT5	A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletio	Marco Gerling	18.12.2025	0	0

# ME Övre buk – Övrigt

Studie		Prövare	Start	Inkl 2025	Total inkl
ERDB	Endoskopiskt Register för Diagnostik och Behandling	Erik von Seth	15.01.2022	57	233
Prev-Ex	Perioperativ ocklusionsträning för att motverka cancerkakexi hos patienter med övre GI cancer - en randomiserad kontrollerad studie.	Yvonne Wengström	01.03.2022	0	21
Personcentrerad smärtbehandling	Utvärdering av vårdens kvalitet från patientens perspektiv: Smärtbehandling. En enkätstudie.	Tina Gustavell	04.04.2024	0	86
CO-SNAR	Completion Sentinel Node resection with or without minimally invasive endoscopic cooperative surgery following non-curative Endoscopic submucosal Dissection	Ioannis Rouvelas	20.01.2025	3	3
DigiCanCare	Utvärdera digitala vårdplaner som stöd för patienter och närstående vid gastrointestinal cancer	Tina Gustavell	20.09.2025	22	22